Skip to main content

Table 1 Characteristics of CBD patients and controls

From: MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features

Variable

CBD patients (N = 230)

Controls (N = 1312)

Age (years)1

70 (46, 96)

69 (45, 92)

Sex

  

 Female

119 (51.7%)

611 (46.6%)

 Male

111 (48.3%)

701 (53.4%)

Age of CBD onset (years)

64 (41, 86)

N/A

Disease duration (years)

6 (2, 16)

N/A

Braak stage

  

 0

27 (13.8%)

N/A

 I

36 (18.4%)

N/A

 II

66 (33.7%)

N/A

 III

53 (27.0%)

N/A

 IV

11 (5.6%)

N/A

 V

2 (1.0%)

N/A

 VI

1 (0.5%)

N/A

Thal phase

  

 0

105 (53.6%)

N/A

 1

35 (17.9%)

N/A

 2

24 (12.2%)

N/A

 3

25 (12.8%)

N/A

 4

3 (1.5%)

N/A

 5

4 (2.0%)

N/A

CB overall tau pathology score

0.77 (0.23, 1.75)

N/A

NFT overall tau pathology score

2.19 (1.13, 2.62)

N/A

AP overall tau pathology score

0.53 (0.24, 1.04)

N/A

NT overall tau pathology score

2.52 (1.24, 2.95)

N/A

  1. CBD corticobasal degeneration, CB coiled bodies, NFT neurofibrillary tangles, AP astrocytic plaques, NT neuropil threads
  2. The sample median (minimum, maximum) is given for age. 1 Age represents age at death in CBD patients and age at blood draw in controls. Information was unavailable in CBD cases for age of CBD onset (N = 42), disease duration (N = 42), Braak stage (N = 34), Thal phase (N = 34), CB overall tau pathology score (N = 34), NFT overall tau pathology score (N = 34), AP overall tau pathology score (N = 34), and NT overall tau pathology score (N = 34)